Literature DB >> 15504845

Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections.

Antonio Oliver1, Bruce R Levin, Carlos Juan, Fernando Baquero, Jesús Blázquez.   

Abstract

Whether or not resistant mutants will be present before the start of antibiotic treatment of an initially susceptible population of bacteria depends on the size of the infecting population, the rate of mutation to resistance, and the amount of time that the population has been maintained. In the present investigation, we argue that for the treatment of chronic infections caused by hypermutable Pseudomonas aeruginosa of the sort frequently found in cystic fibrosis patients, mutants resistant to all single antipseudomonal drugs will almost invariably be present in a high proportion at the onset of treatment, and consequently, these strains should be considered resistant to all agents when they are used as monotherapy. Using a construct of P. aeruginosa strain PAO1 with a mutS deletion (strain PAODeltamutS), we show that when in vitro populations of less than 5 x 10(4) seemingly susceptible hypermutable bacteria are confronted with any of 11 antipseudomonal agents, mutants for which the MICs and the minimum bactericidal concentrations are in the range of clinical resistance will almost invariably ascend to dominance within 24 to 36 h. This does not occur for PAO1 without the mutS deletion. The results of our detailed analysis of this evolution of acquired resistance to two of these antibiotics, imipenem and ciprofloxacin, indicate that although the rates of mutation to resistance in PAODeltamutS are on the order of 1 x 10(-6) per generation, resistant mutants are very likely to either be present in cultures of between 2 x 10(4) and 4 x 10(4) bacteria or arise after the bacterial populations are confronted with antibiotics. We also demonstrate with in vitro experiments that the problem of acquired resistance to treatment with single antibiotics can be thwarted by combination therapy with pairs of antibiotics of different classes with synergistic activities. We discuss the clinical implications of our analysis of these observations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504845      PMCID: PMC525420          DOI: 10.1128/AAC.48.11.4226-4233.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance.

Authors:  M C Negri; M Lipsitch; J Blázquez; B R Levin; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Fluctuation analysis: the probability distribution of the number of mutants under different conditions.

Authors:  F M Stewart; D M Gordon; B R Levin
Journal:  Genetics       Date:  1990-01       Impact factor: 4.562

3.  Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance.

Authors:  M Lipsitch; B R Levin
Journal:  Int J Tuberc Lung Dis       Date:  1998-03       Impact factor: 2.373

4.  A modified Luria-Delbrück fluctuation assay for estimating and comparing mutation rates.

Authors:  G J Crane; S M Thomas; M E Jones
Journal:  Mutat Res       Date:  1996-07-22       Impact factor: 2.433

5.  Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.

Authors:  S Westbrock-Wadman; D R Sherman; M J Hickey; S N Coulter; Y Q Zhu; P Warrener; L Y Nguyen; R M Shawar; K R Folger; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Luria-Delbrück fluctuation experiments: design and analysis.

Authors:  M E Jones; S M Thomas; A Rogers
Journal:  Genetics       Date:  1994-03       Impact factor: 4.562

7.  Periodic selection, infectious gene exchange and the genetic structure of E. coli populations.

Authors:  B R Levin
Journal:  Genetics       Date:  1981-09       Impact factor: 4.562

8.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

9.  Selective media for the quantitation of bacteria in cystic fibrosis sputum.

Authors:  K Wong; M C Roberts; L Owens; M Fife; A L Smith
Journal:  J Med Microbiol       Date:  1984-04       Impact factor: 2.472

10.  Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa.

Authors:  S E West; H P Schweizer; C Dall; A K Sample; L J Runyen-Janecky
Journal:  Gene       Date:  1994-10-11       Impact factor: 3.688

View more
  54 in total

1.  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Authors:  Hsun-Cheng Su; Kevin Ramkissoon; Janet Doolittle; Martha Clark; Jainab Khatun; Ashley Secrest; Matthew C Wolfgang; Morgan C Giddings
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

2.  Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria.

Authors:  Ryan T Cirz; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections.

Authors:  M D Maciá; A Mena; N Borrell; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

Review 4.  A practical guide to measuring mutation rates in antibiotic resistance.

Authors:  Cassie F Pope; Denise M O'Sullivan; Timothy D McHugh; Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2008-02-04       Impact factor: 5.191

5.  Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

Authors:  B Henrichfreise; I Wiegand; W Pfister; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

6.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

7.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

8.  Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa.

Authors:  Irith Wiegand; Alexandra K Marr; Elena B M Breidenstein; Kristen N Schurek; Patrick Taylor; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

9.  Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Kai-Tai Chang; Kamilia Abdelraouf; Cristina G Brioso; Magdalene Ameka; Laurie A McCaskey; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients.

Authors:  Olivia Gutiérrez; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.